Показано 0 из 0
Дата |
---|
19:25 |
02.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
19.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
20.25
|
20.49
|
20.38
|
20.17
|
20.39
|
20.17
|
|
|
|
|
20.48
|
20.72
|
20.10
|
20.10
|
20.49
|
20.49
|
|
|
|
|
21.95
|
22.21
|
21.81
|
21.47
|
21.98
|
21.98
|
|
|
|
|
22.01
|
22.27
|
21.81
|
21.64
|
22.06
|
22.06
|
|
|
|
|
22.06
|
22.26
|
21.76
|
21.76
|
22.03
|
22.03
|
|
|
|
|
21.86
|
22.12
|
21.50
|
21.49
|
21.70
|
21.63
|
|
|
|
|
22.04
|
22.26
|
21.57
|
21.55
|
22.05
|
22.05
|
|
|
|
|
21.79
|
22.00
|
21.09
|
21.06
|
21.74
|
21.74
|
|
|
|
|
21.39
|
21.64
|
20.91
|
20.89
|
21.39
|
21.39
|
|
|
|
|
21.01
|
21.26
|
20.59
|
20.59
|
20.83
|
20.80
|
|
|
|
|
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.